GEHC 44th Annual J.P.… Presentation

Page 1

Page 2

© 2026 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. Forward-looking statements and additional information 2 This presentation contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” “forecast,” “target,” “guidance,” “outlook,” and simi lar expressions. These forward-looking statements may include, but are not limited to, statements about our business and expected financial performance, financial condition, and results of operations, including r evenue, revenue growth, profit, taxes, earnings per share, and cash flows, and our outlook and medium-term financial targets; statements about our acquisition of Intelerad, including the completion and expected results thereof; the impacts of macroeconomic and market conditions, including the impact of tariffs and other trade restrictions, and volatility on the Company’s business, operations, financial results, and financial position and on supply chains and the world economy; operational performance; demand in the global markets in which we operate; and our strategy, innovation, and investments. These forward -looking statements involve risks and uncertainties, many of which are beyond our control. Factors that could cause our actual results to differ materially from those described in our forward -looking statements include, but are not limited to, operating in highly competitive markets; global geopolitical and economic instability, including as a result of changes in trade and tariff policy, and international conflic ts and tensions, including between Ukraine and Russia and in the Middle East; public health crises, epidemics, and pandemics, and their effects on our business; changes in third -party and government reimbursement processes, rates, and contractual relationships, including related to government shutdowns, and changes in the mix of public and private payers; demand for our products, services, or solutions an d factors that affect that demand; developments in the market in China; our ability to control increases in healthcare costs and any subsequent effect on demand for our products, services, or solutions; our ab ility to successfully complete strategic transactions; the impacts related to our increasing focus on and investment in cloud, edge computing, artificial intelligence, and software offerings; management of o ur supply chain and our ability to cost-effectively secure the materials we need to operate our business; disruptions in our operations; the actions or inactions of third parties with whom we partner and the v arious collaboration, licensing, and other partnerships and alliances we have with third parties; the impact of potential information technology, cybersecurity, or data security breaches; maintenance and prot ection of our intellectual property rights, as well as maintenance of successful research and development efforts with respect to commercially successful products and technologies; our ability to attract an d/or retain key personnel and qualified employees; environmental, social, and governance matters; compliance with the various legal, regulatory, tax, privacy, and other laws to which we are subject, such as the Foreign Corrupt Practices Act and similar anti-corruption and anti-bribery laws globally, and related changes, claims, inquiries, investigations, or actions; the impact of potential product liability claim s; and our level of indebtedness, as well as our general ability to comply with covenants under our debt instruments, and any related effect on our business. Please also see Item 1A, “Risk Factors” of our Annual Rep ort on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission and any updates or amendments we make in future filings. There may be other factors not pr esently known to us or which we currently consider to be immaterial that could cause our actual results to differ materially from those projected in any forward -looking statements we make. We do not undertake any obligation to update or revise our forward -looking statements except as required by applicable law or regulation. Non-GAAP Financial Measures This presentation contains non-GAAP financial measures. See appendix for more information on our Outlook. Financial Rounding Certain columns and rows throughout this document may not sum due to the use of rounded numbers. Percentages presented are ca lculated from the underlying whole-dollar amounts. Product Status Not all products or features are available in all markets. The information presented here may involve technologies and concep ts in development that are not products and may never become products. For Technology in Development, the technologies or concepts are not being offered for sale and are not cleared or approved by the U.S. FDA or any other global regulator for commercial availability.

Page 3

© 2026 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. Strategic framework 3 Create a world where healthcare has no limitsPurpose: Why we exist Strategic pillars: Business priority areas People, patients and culture Serve our people, patients and customers Lead with a lean mindset Empower entrepreneurial spirit Deliver the future of healthcare Winning with inclusive teams Foundation + operating principles Moving from an imaging company to healthcare solutions company Positioning GEHC in faster growing markets, organically and inorganically Driving agility and margin expansion Precision care Growth acceleration Business optimization Always with the highest integrity

Page 4

© 2026 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. Executing on our strategy in 2025 Enabled by Heartbeat - GE HealthCare’s proprietary lean business system 4 Create a world where healthcare has no limits Precision care Growth acceleration Business optimization • Showcased 40 new products and solutions at RSNA • Furthered investment in AI-enabled medical devices; topped FDA’s list of AI authorizations with 115(1) • Advanced growth in contrast and radiopharmaceuticals, including successful Flyrcado launch • Deployed $3.5B in R&D investment since spin(2) • Positioned to accelerate top-line growth with innovation • Signed ~200 enterprise deals since spin(2); ~$7B lifecycle value(2) • Ongoing productivity improvements to drive margin expansion • Effectively navigating a dynamic macro environment • Advancing lean to enhance customer satisfaction and margin expansion 1) Artificial Intelligence and Machine Leaning (AI/ML) – Enabled Medical Devices, U.S. Food & Drug Administration. 2) As of 3Q'25.

Page 5

© 2026 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. Imaging Advanced Visualization Solutions (AVS) Patient Care Solutions (PCS) Pharmaceutical Diagnostics (PDx) Revenue(1) $9.1B $5.3B $3.1B $2.8B EBIT margin(1) 10.2% 22.3% 7.8% 30.8% Our business segments by the numbers $90 billion Estimated total addressable market in 2023(2) Estimated by 2028(2) Care journey, AI and digital innovation driving future growth 1) TTM 3Q 2025; Results recast in line with move of Image Guided Therapies from Imaging to Advanced Visualization Solutions. 2) Based on GE HealthCare estimates and Signify Research for digital solutions. $110+ billion 5 (Includes tariff impact)

Page 6

© 2026 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. Introducing Heartbeat: GE HealthCare’s proprietary lean business system A catalyst for continuous improvement that drives sustainable growth and elevates excellence in daily work Culture Financial performance Transformation + breakthroughs (Hoshin Kanri) Operating results Innovation performance Our purpose and strategy executed through Heartbeat ... … driving measurable results 6

Page 7

© 2026 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. Driving growth with a new wave of innovation 7 NPIs expected to help drive 1-2% of growth in medium-term Imaging PDx Omni 128cm Total Body PET/CT(2) StarGuide GX (2) Photonova Spectra(1) AI-enabled SIGNA Sprint with Freelium(1) SIGNA Bolt 3T(1) AVS Vivid Pioneer Allia Moveo PCS CareIntellect for Perinatal Carestation 850 Flyrcado PET MPI agent Not all products are available in all markets. 1) 510(k) pending with the U.S. FDA. Not CE Marked. Not available for sale in the United States, Europe, Canada, or any other re gion. 2) CE marked. Available for sale in EU member states. Not approved or cleared by the U.S. FDA. Not available for sale in the U.S. and other non- EU member state countries. Pristina Via with Pristina Recon DL

Page 8

© 2026 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. Advancing precision care through radiopharmaceutical innovation 8 PET, radiopharmaceuticals, and AI-enabled workflow tools create an integrated precision imaging ecosystem U.S. reimbursement reset Clinical guidelines and evidence Nuclear medicine market momentum Breakthroughs in PET imaging Broad manufacturing reach in U.S. Key drivers to growth acceleration Proprietary GEHC PET imaging agents

Page 9

© 2026 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. 9 Intelerad acquisition* accelerates our growth strategy *Transaction expected to be completed in first half of 2026; subject to customary closing conditions and regulatory approvals • Creates a cloud-first, AI-enabled imaging ecosystem across inpatient, outpatient and ambulatory, and teleradiology • Intelerad revenue growing in low-double-digit range annually; expected to accelerate under GEHC • Integration to be enabled by Heartbeat Immediately accretive to top-line growth and Adjusted EBIT margin Slightly dilutive to Adjusted EPS in short- term; plans to offset with cost efficiencies 90% recurring revenue High single-digit ROIC by year 5 Intelerad meets disciplined M&A criteria

Page 10

© 2026 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. Platforming Organizational simplification Structural optimization Variable cost productivity Optimizing our business for margin expansion 10 Strong margin expansion opportunity enabled by Heartbeat Lean initiatives drive continuous improvement Expect 2026 tariff expense to be below the forecasted 2025 level of $265M • Structural changes to our supply chain … multi-sourcing through our factories and suppliers • SKU rationalization to reduce complexity • Expanded USMCA certification • Free trade zones • Evaluating pricing decisions

Page 11

© 2026 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. Aligning capital allocation to strategy 11 Creating long-term value through growth and innovation enabled by robust and consistent cash flow 1) As of 3Q’25. 2) As of 3Q'25, adjusted for Nov'25 bond maturity that was refinanced Jun'25. Organic investment driving growth Strategic M&A Criteria Returning cash to shareholders Maintaining strong balance sheet $3.5B (1) Cumulative R&D investment since spin $200M (1) Shares repurchased since 2Q 2025 $1.5B (2) Debt repaid since spin Committed to continued investment in innovation Paying quarterly dividend to shareholders Executing opportunistic share buybacks Committed to Investment Grade rating 8 Acquisitions announced since spin Accelerates growth; near- term EPS accretion Target recurring revenue ROIC reaching HSD+ within 5 years

Page 12

© 2026 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. Medium-term financial framework Medium-term 2026–2028 outlook Path to achieving targets remains clear as we navigate macroeconomic environment Driving top line growth through innovation Progress to date gives us continued confidence in ability to execute Multiple levers to deliver on 20%+ Adjusted EBIT margin* target MSD Organic revenue growth* High-teens to 20%+ Adjusted EBIT margin* HSD to LDD Adjusted EPS growth*(1) 90%+ Free cash flow conversion* * Non-GAAP financial measure. See appendix for more information on our Outlook. .1) Excludes future impact of capital deployment. 12

Page 13

© 2026 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. Path to accelerate shareholder value and growth 13 Progress on innovation positions us to accelerate growth Differentiated market position across equipment leveraging AI and broad PDx portfolio Robust cash flow + disciplined capital allocation strategy aimed at driving strong returns Top- and bottom-line execution enhanced by Heartbeat

Page 14

Page 15

© 2026 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. The non-GAAP financial measures presented in this presentation are supplemental measures of GE HealthCare’s performance and its liquidity that the Company believes will help investors understand its financial condition, cash flows, and operating results, and assess its future prospects. When read in conjunction with the Company’s U.S. GAAP results, these non-GAAP financial measures provide a baseline for analyzing trends in GE HealthCare’s underlying businesses and can be used by management as one basis for making financial, operational, and planning decisions. Descriptions of the reported non-GAAP measures are included below. The Company reports Organic revenue and Organic revenue growth rate to provide management and investors with additional understanding and visibility into the underlying revenue trends of its established, ongoing operations, as well as provide insights into overall demand for our products and services. To calculate these measures, the Company excludes the effect of acquisitions, dispositions, and foreign currency rate fluctuations. The Company reports Adjusted gross profit, Adjusted gross profit margin, EBIT, Adjusted EBIT, Adjusted EBIT margin, Adjusted net income, and Adjusted earnings per share to provide management and investors with an additional understanding of its business by highlighting the results from ongoing operations and the underlying profitability factors, on a normalized basis. To calculate these measures the Company excludes the following adjustments as applicable: Interest and other financial charges – net, Net (income) loss attributable to noncontrolling interests, Non- operating benefit (income) costs, Benefit (provision) for income taxes and certain tax related adjustments, and certain non-recurring and/or non-cash items. GE HealthCare may from time to time consider excluding other non-recurring items to enhance comparability between periods. Adjusted gross profit margin and Adjusted EBIT margin are calculated by taking Adjusted gross profit or Adjusted EBIT, divided by Total revenues for the same period. The Company reports Adjusted tax expense and Adjusted ETR to provide management and investors with a better understanding of the normalized tax rate applicable to the business and provide more consistent comparability across periods. Adjusted tax expense excludes the income tax related to the pre-tax income adjustments included as part of Adjusted net income and certain income tax adjustments, such as adjustments to deferred tax assets or liabilities. The Company may from time to time consider excluding other non-recurring tax items to enhance comparability between periods. Adjusted ETR is Adjusted tax expense divided by income before income taxes less the pre-tax income adjustments referenced above. The Company reports Free cash flow and Free cash flow conversion to provide management and investors with an important measure of the ability to generate cash on a normalized basis and provide insight into the Company’s flexibility to allocate capital. Free cash flow is Cash from (used for) operating activities – continuing operations including cash flows related to the additions and dispositions of PP&E and additions of internal-use software. Free cash flow does not represent residual cash flows available for discretionary expenditures, due to the fact that the measure does not deduct the capital required for debt repayments. Free cash flow conversion is calculated by taking Free cash flow divided by Adjusted net income. Management recognizes that these non-GAAP financial measures have limitations, including that they may be calculated differently by other companies or may be used under different circumstances or for different purposes. In order to compensate for the discussed limitations, management does not consider these measures in isolation from or as alternatives to the comparable financial measures determined in accordance with U.S. GAAP. No single financial measure should be relied on to evaluate our business. Non-GAAP financial measures 15

Page 16

© 2026 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. GE HealthCare calculates forward-looking non-GAAP financial measures, including Organic revenue growth, Adjusted EBIT margin, Adjusted ETR, Adjusted EPS, and Free cash flow based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. GE HealthCare does not provide reconciliations of these forward-looking non-GAAP financial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or dispositions, timing and magnitude of restructuring activities, and revaluation of strategic investments, amongst other items. The timing and amounts of these items are uncertain and could have a substantial impact on GE HealthCare’s results in accordance with GAAP. Non-GAAP financial measures in outlook 16

Slides